Annovis’ cash and cash equivalents totaled $15.3 million as of September 30, 2025, compared to $10.6 million as of December 31, 2024. This includes gross proceeds from its recent $6.0 million and $3.4 million registered direct offerings in October, enabling the Company to fund its operations to the third quarter of 2026. Annovis had 20.2 million shares of common stock outstanding as of September 30, 2025.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANVS:
- Optimistic Buy Rating for Annovis Bio Amid Promising Alzheimer’s Clinical Developments
- Annovis Bio says all 84 sites fully activated for Phase 3 study in early AD
- Annovis Bio Announces Securities Purchase Agreement
- Annovis Bio prices 1.67M shares at $2.05 in registered direct offering
- Annovis Bio Announces $6M Stock Offering